Involvement of Lipids and Lipid Mediators in Inflammation and Atherogenesis
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Atherosclerosis is the pathophysiological basis for major diseases, such as coronary heart disease, cerebral stroke, and peripheral arterial disease, which have become epidemic in modern Western society. Atherosclerosis has a complex nature that involves mutually related immune and metabolic mechanisms. Many cells of the vascular wall and peripheral bloodstream, including endothelial cells, monocytes and macrophages, platelets, and others, are involved in the development and progression of atherosclerosis. These cells perform a number of innate immune functions, disorders of which are associated with atherosclerosis. Furthermore, lipids are not only a morphological substrate but also important participants in the development of atherosclerosis. They are involved in the development and resolution of inflammation and mediate vascular cell function.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - (2024) vom: 19. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kotlyarov, Stanislav [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0109298673303369240312092913 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369941705 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369941705 | ||
| 003 | DE-627 | ||
| 005 | 20240320235410.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0109298673303369240312092913 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369941705 | ||
| 035 | |a (NLM)38504569 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kotlyarov, Stanislav |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Involvement of Lipids and Lipid Mediators in Inflammation and Atherogenesis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Atherosclerosis is the pathophysiological basis for major diseases, such as coronary heart disease, cerebral stroke, and peripheral arterial disease, which have become epidemic in modern Western society. Atherosclerosis has a complex nature that involves mutually related immune and metabolic mechanisms. Many cells of the vascular wall and peripheral bloodstream, including endothelial cells, monocytes and macrophages, platelets, and others, are involved in the development and progression of atherosclerosis. These cells perform a number of innate immune functions, disorders of which are associated with atherosclerosis. Furthermore, lipids are not only a morphological substrate but also important participants in the development of atherosclerosis. They are involved in the development and resolution of inflammation and mediate vascular cell function | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a innate immune system | |
| 650 | 4 | |a lipids | |
| 650 | 4 | |a macrophages | |
| 650 | 4 | |a platelets | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d 1997 |g (2024) vom: 19. März |w (DE-627)NLM093833857 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0109298673303369240312092913 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 03 | ||